Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ANI PHARMACEUTICALS INC (ANIP)
|
Add to portfolio |
|
|
|
| Price: |
$47.15
| | Metrics |
| OS: |
20.3
|
M
| |
-2
|
% ROE
|
| Market cap: |
$957
|
M
| |
10
|
% ROIC
|
|
Net debt:
|
$124
|
M
| |
1.3
|
x Debt/EBITDA
|
|
EV:
|
$1.08
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$96.3
|
M
| |
11.2
|
x EV/EBITDA
|
|
EBIT
|
$35.6
|
M
| |
30.4
|
x EV/EBIT
|
| EPS |
($0.45)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 316.4 | 216.1 | 208.5 | 206.5 | 201.6 | 176.8 | 128.6 | 76.3 |
| Revenue growth | 46.4% | 3.7% | 0.9% | 2.5% | 14.0% | 37.5% | 68.5% | 36.4% |
| Cost of goods sold | 142.5 | 101.9 | 98.4 | 69.9 | 73.0 | 79.0 | 48.8 | 12.7 |
| Gross profit | 173.8 | 114.2 | 110.1 | 136.7 | 128.6 | 97.8 | 79.8 | 63.6 |
| Gross margin | 54.9% | 52.9% | 52.8% | 66.2% | 63.8% | 55.3% | 62.1% | 83.4% |
| Selling, general and administrative | 124.0 | 84.3 | 65.0 | 55.8 | 44.1 | 31.6 | 27.8 | 21.2 |
| Research and development | 22.3 | 11.4 | 16.0 | 19.8 | 15.4 | 9.1 | 2.9 | 2.9 |
| EBITA | 27.5 | 13.8 | 24.3 | 56.6 | 67.1 | 55.9 | 48.2 | 38.9 |
| EBITA margin | 8.7% | 6.4% | 11.7% | 27.4% | 33.3% | 31.6% | 37.4% | 51.0% |
| Amortization of intangibles | 49.5 | 41.8 | 39.9 | 40.2 | 31.7 | 26.7 | 21.4 | 6.2 |
| EBIT | -22.0 | -28.0 | -15.6 | 16.4 | 35.4 | 29.2 | 26.8 | 32.7 |
| EBIT margin | -6.9% | -12.9% | -7.5% | 8.0% | 17.5% | 16.5% | 20.8% | 42.8% |
| Pre-tax income | -62.7 | -56.1 | -26.0 | 3.2 | 20.1 | 16.3 | 8.7 | 21.7 |
| Income taxes | -14.8 | -13.5 | -3.4 | -2.9 | 4.6 | 17.4 | 4.7 | 6.4 |
| Tax rate | 23.6% | 24.0% | 13.1% | | 22.7% | 106.6% | 54.7% | 29.3% |
| Net income | -49.5 | -42.8 | -22.5 | 6.1 | 15.5 | -1.1 | 3.9 | 15.4 |
| Net margin | -15.7% | -19.8% | -10.8% | 3.0% | 7.7% | -0.6% | 3.1% | 20.1% |
| |
| Diluted EPS | ($3.05) | ($3.40) | ($1.88) | $0.51 | $1.32 | ($0.09) | $0.34 | $1.33 |
| Shares outstanding (diluted) | 16.3 | 12.6 | 12.0 | 12.0 | 11.8 | 11.5 | 11.6 | 11.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|